Suppr超能文献

小儿心脏重症监护患者对静脉补充氯化钾的反应。

Response to intravenous potassium chloride supplementation in pediatric cardiac intensive care patients.

作者信息

Knudson Jarrod D, Lowry Adam W, Price Jack F, Moffett Brady S

机构信息

Division of Pediatric Cardiology, Department of Pediatrics, University of Mississippi Medical Center/Batson Children's Hospital, 2500 North State Street, Jackson, MS 39216, USA.

出版信息

Pediatr Cardiol. 2013 Apr;34(4):887-92. doi: 10.1007/s00246-012-0565-4. Epub 2012 Nov 4.

Abstract

Potassium chloride (KCl) supplementation is common among critically ill children. Intravenous (IV) KCl supplementation for pediatric patients is poorly characterized. This study aimed to examine the efficacy and safety of IV KCL and to determine factors affecting patient responses to IV KCL in the pediatric cardiac intensive care unit (CICU). A retrospective review of 211 children (794 KCl doses) undergoing cardiac surgery or a hospital stay for heart failure in the CICU of a tertiary care teaching and referral children's hospital in 2011 was performed. Demographic data, weight, height, creatinine, and concomitant medications during each KCl dose were recorded and analyzed. Body surface area (BSA), creatinine clearance, and change in [K(+)] were calculated. The median age of the children was 4 months (range, 10 days-18 years). In this study, 151 KCl doses were administered to neonates (19 %), 307 doses (39 %) to females, and 510 doses (64 %) to patients with a BSA smaller than 0.33 m(2) (a group with relative renal insufficiency). The mean KCl dose was 0.97 ± 0.006 mEq/kg. No adverse events were associated with IV KCl administration. Blood/plasma [K(+)] increased 0.8 ± 0.02 mEq/L. The responses to KCl did not differ significantly between males and females, between neonates and children, or between patients with a BSA smaller than 0.33 m(2) and those with a BSA of 0.33 m(2) or larger. The responses to IV KCl were attenuated by concomitant furosemide (p = 0.01), amphotericin B (p < 0.01), and KCl in parenteral nutrition (p < 0.01). The responses were augmented by concomitant enalapril (p = 0.03), ethacrynic acid (p < 0.001), and hemodialysis (p < 0.01). Intravenous KCl can be administered safely for CICU patients. Responses to KCl are altered when it is given with certain medications. Intravenous KCl should be used cautiously in children receiving angiotensin-converting enzyme inhibitors. Future studies are needed for further characterization of factors affecting responses to IV KCl in children.

摘要

在危重症儿童中,补充氯化钾(KCl)很常见。儿科患者静脉补充氯化钾的情况目前了解甚少。本研究旨在探讨静脉补钾的疗效和安全性,并确定影响儿科心脏重症监护病房(CICU)患者对静脉补钾反应的因素。对2011年一家三级护理教学及转诊儿童医院CICU中接受心脏手术或因心力衰竭住院的211名儿童(794次氯化钾给药)进行了回顾性研究。记录并分析了每次氯化钾给药期间的人口统计学数据、体重、身高、肌酐及伴随用药情况。计算了体表面积(BSA)、肌酐清除率及血钾浓度([K⁺])的变化。儿童的中位年龄为4个月(范围10天至18岁)。本研究中,151次氯化钾给药用于新生儿(19%),307次(39%)用于女性,510次(64%)用于体表面积小于0.33 m²的患者(相对肾功能不全组)。氯化钾的平均给药剂量为0.97±0.006 mEq/kg。静脉补钾未出现不良事件。血/血浆血钾浓度升高0.8±0.02 mEq/L。男性与女性、新生儿与儿童、体表面积小于0.33 m²的患者与体表面积≥0.33 m²的患者对氯化钾的反应无显著差异。同时使用呋塞米(p = 0.01)、两性霉素B(p < 0.01)及肠外营养中的氯化钾(p < 0.01)会减弱对静脉补钾的反应。同时使用依那普利(p = 0.03)、依他尼酸(p < 0.001)及血液透析(p < 0.01)会增强反应。静脉补钾对CICU患者是安全的。与某些药物合用时,对氯化钾的反应会改变。接受血管紧张素转换酶抑制剂治疗的儿童应谨慎使用静脉补钾。未来需要进一步研究以明确影响儿童对静脉补钾反应的因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验